---
title: "Nucala (mepolizumab) in severe eosinophilic asthma: Specific populations questions"
description: "Specific populations questions on Nucala (mepolizumab) in severe eosinophilic asthma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Adolescents, Pediatric use, and Pregnancy and breastfeeding. Questions: Does Nucala work for adolescents 12 to 17 with severe asthma? Is Nucala approved for children with severe asthma? Is Nucala safe during pregnancy? 3 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/specific-populations"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Nucala (mepolizumab) in severe eosinophilic asthma: Specific populations questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Nucala](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF)

Specific populations questions that apply to every indication of Nucala are on [Nucala (mepolizumab), all indications: Specific populations](https://www.evicenter.com/medical-information/nucala/specific-populations).

## Adolescents

<a id="nucala-adolescents"></a>

### Does Nucala work for adolescents 12 to 17 with severe asthma?

> “Use of NUCALA in adolescents aged 12 to 17 years is supported by evidence from adequate and 
> well-controlled trials in adults and adolescents. A total of 28 adolescents aged 12 to 17 years 
> with severe asthma were enrolled in the Phase 3 asthma trials. Of these, 25 were enrolled in the 
> 32-week exacerbation trial (MENSA) and had a mean age of 14.8 years. Patients had a history of 
> 2 or more exacerbations in the previous year despite regular use of medium- or high-dose ICS 
> plus additional controller(s) with or without OCS and had blood eosinophils of ≥150 cells/mcL at 
> screening or ≥300 cells/mcL within 12 months prior to enrollment. [See Clinical Studies (14.1).] 
> Patients had a reduction in the rate of exacerbations that trended in favor of NUCALA.”

Source: [NUCALA: Prescribing information, page 13, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=13)

> “The safety profile observed in adolescents was 
> generally similar to that of the overall population in the Phase 3 studies [see Adverse Reactions 
> (6.1)].”

Source: [NUCALA: Prescribing information, page 14, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=14)

## Pediatric use

<a id="nucala-pediatric-use"></a>

### Is Nucala approved for children with severe asthma?

> “The safety and effectiveness of NUCALA for severe asthma, and with an eosinophilic 
> phenotype, have been established in pediatric patients aged 6 years and older.”

Source: [NUCALA: Prescribing information, page 13, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=13)

> “The safety and effectiveness in pediatric patients aged younger than 6 years with severe asthma 
> have not been established.”

Source: [NUCALA: Prescribing information, page 14, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=14)

## Pregnancy and breastfeeding

<a id="nucala-pregnancy"></a>

### Is Nucala safe during pregnancy?

> “The data on pregnancy exposure are insufficient to inform on drug-associated risk. Monoclonal 
> antibodies, such as mepolizumab, are transported across the placenta in a linear fashion as 
> pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the 
> second and third trimester of pregnancy. In a prenatal and postnatal development study 
> conducted in cynomolgus monkeys, there was no evidence of fetal harm with intravenous 
> administration of mepolizumab throughout pregnancy at doses that produced exposures up to 
> approximately 9 times the exposure at the maximum recommended human dose (MRHD) of 
> 300 mg subcutaneous (see Data).”

Source: [NUCALA: Prescribing information, page 12, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=12)

> “Disease-Associated Maternal and/or Embryofetal Risk: In women with poorly or moderately 
> controlled asthma, evidence demonstrates that there is an increased risk of preeclampsia in the 
> mother and prematurity, low birth weight, and small for gestational age in the neonate. The level 
> of asthma control should be closely monitored in pregnant women and treatment adjusted as 
> necessary to maintain optimal control.”

Source: [NUCALA: Prescribing information, page 12, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=12)

Note: The 300 mg maximum recommended human dose is the EGPA and HES dose; the severe asthma dose is 100 mg every 4 weeks (40 mg for ages 6 to 11).

## Related pages
- [Medical information: Nucala (mepolizumab): Severe eosinophilic asthma](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma)
- [Indication](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/access-and-coverage)
